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Many cancers are associated with functional mutations
which now can be readily identified using new DNA
sequencing methods. Sequence information is now used
for the generation of personalized cancer vaccines with
promising clinical benefit [1]. Intelligent ways to select
the relevant, tumor-specific protein-coding mutations
are applied to filter the large number of identified muta-
tion to a manageable number. Besides, there is an
increasing data pool of mutations, both germline and
somatic, the latter frequently even with attached addi-
tional information on the tissue and histology.
Even though the use of actual sequence of an indivi-
dual patient is the optimal basis for treatment and
immune monitoring it is quite expensive relatively slow
to obtain this information. As a fast tool with broad
applicability across patient cohorts peptide libraries
could find an application in cases where the individual
sequence is not (yet) available.
Pools of antigen peptides are frequently for T cell sti-
mulation in T cell assays and even for immune stimula-
tion for treatment. Such peptide libraries are well suited
for presenting sequence diversity. However, libraries
used today normally consist of overlapping peptides of a
wild-type antigen sequence. The concept was already
extended for the presentation of sequence diversity in
antigens of pathogens as HIV where sequence diversity
between individual viruses poses many challenges. For
the ENV protein an increase in sequence coverage from
10 % to 34 % was achieved. Due to the limited number
of peptides a complex filtering of sequence data has to
be applied to enrich the library with peptides carrying
different tumor-specific and ideally functionally relevant
mutations.
Our aim is to generate peptide libraries for specific
antigens which represent a generic cancer mutanome
applicable to a large number of individual patients based
on available databases as the catalogue of somatic muta-
tions in cancer and epitope information from the
immune epitope database and prediction algorithms.
One library type can contain the full length sequence
of the antigen enriched by peptides representing over-
lapping scans for relevant mutations. Alternatively,
known or predicted epitopes can be selected and the
mutated epitopes can be included. However, mutations
can lead to the formation of new epitopes and mutated
epitopes can escape from MHC-binding. Epitope predic-
tion can help to account for these effects.
We have built a pipeline for the efficient generation of
such libraries which will be manufactured.
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